Shots:

• Foghorn to receive $300M up front in cash, $80M in equity investment at $20/share, ~$1.3B in development & commercialization milestones along with royalties on Ex-US sales. The companies will share 50/50 in the US economics
• The collaboration will leverage Foghorn's Gene Traffic Control Platform & use its precision biology to develop novel oncology therapies targeting genetic dependencies within the chromatin regulatory system
• Foghorn will be responsible for the discovery & early research activities for a BRM-selective program & 3 additional target programs. Lilly will lead development & commercialization activities in operational activities & cost-sharing

Ref: Lilly | Image: Lilly